SA
ESPR

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

Esperion Therapeutics is a specialty pharmaceutical company commercializing oral, non-statin LDL-cholesterol lowering therapies (bempedoic acid) for cardiovascular disease patients. The company markets NEXLETOL and NEXLIZET in the US and has licensed rights to Daiichi Sankyo for ex-US markets. Recent 186% revenue growth reflects commercial ramp following positive CLEAR Outcomes cardiovascular outcomes trial data published in March 2023, which demonstrated 13% reduction in major adverse cardiovascular events.

HealthcareSpecialty Pharmaceutical - Cardiovascular Therapeuticshigh - Fixed cost base includes commercial infrastructure (sales force, marketing), R&D for lifecycle management, and G&A. Manufacturing is outsourced with variable COGS. As revenue scales beyond current $300M run-rate, incremental margins should expand significantly given 79% gross margins and relatively fixed SG&A base of approximately $200M annually. Company achieved positive operating margin of 16% in TTM, suggesting inflection point reached.

Business Overview

01NEXLETOL (bempedoic acid monotherapy) US product sales - estimated 45-50% of revenue
02NEXLIZET (bempedoic acid + ezetimibe combination) US product sales - estimated 45-50% of revenue
03Royalty and milestone payments from Daiichi Sankyo ex-US commercialization - estimated 5-10% of revenue

Esperion generates revenue through direct sales to specialty pharmacies and wholesalers in the US cardiovascular market. The company targets statin-intolerant patients and those requiring additional LDL-lowering beyond statins, addressing an estimated 30-40 million patient population in the US. Pricing power derives from differentiated mechanism of action (ATP citrate lyase inhibitor) and outcomes data showing cardiovascular event reduction. Gross margins of 79% reflect low cost of goods for small molecule oral therapy. The company maintains a specialized 120-person sales force focused on high-prescribing cardiologists and endocrinologists. Ex-US, Daiichi Sankyo handles commercialization with Esperion receiving tiered royalties on net sales.

What Moves the Stock

Quarterly prescription volume trends (TRx and NBRx data from IQVIA) - market expects continued 30-40% sequential growth

Payer coverage expansion and prior authorization removal - currently ~80% commercial lives covered, Medicare Part D formulary positioning critical

Daiichi Sankyo ex-US launch progress in Europe (EMA approved 2020) and Japan - royalty revenue acceleration

Gross-to-net pricing adjustments and rebate trends - currently running ~50% gross-to-net, in line with specialty pharma

Cash burn rate and path to sustained profitability - company near breakeven operationally but negative FCF of $30M TTM

Watch on Earnings
Total prescriptions (TRx) and new prescriptions (NBRx) growth rates from IQVIA weekly dataNet product revenue and gross-to-net percentage (rebates, discounts, co-pay assistance)Operating expense discipline and adjusted EBITDA trajectory toward sustained profitabilityEx-US royalty revenue from Daiichi Sankyo European and Japanese commercializationCash position and quarterly burn rate - liquidity runway critical given negative FCF

Risk Factors

Competitive threat from PCSK9 inhibitors (Repatha, Praluent) gaining oral formulations or pricing becoming more aggressive - injectable biologics currently $5,000-6,000 annually versus NEXLETOL ~$4,000

Inclisiran (Leqvio) twice-yearly injectable gaining market share in statin-intolerant segment - Novartis pricing at $3,250 annually with superior dosing convenience

Medicare Part D negotiation risk under Inflation Reduction Act - products could face price controls if selected for negotiation in 2027-2029 cycles

Generic bempedoic acid entry post-patent expiration (key composition of matter patents expire 2030-2032) - limited exclusivity runway

Statin manufacturers (Pfizer Lipitor generic, AstraZeneca Crestor) maintaining dominance through inertia and $10-20/month generic pricing despite tolerability issues in 10-15% of patients

Amgen and Sanofi/Regeneron expanding PCSK9 inhibitor access through aggressive rebating and outcomes data - cardiovascular outcomes superiority versus bempedoic acid unclear in head-to-head

Novartis Leqvio gaining preferred formulary status due to twice-yearly dosing versus daily oral - adherence advantage in real-world setting

Negative tangible book value and accumulated deficit of approximately $1.8B - company has burned significant cash reaching commercialization

Current ratio of 1.0x indicates tight liquidity - cash position of ~$150M provides 12-18 month runway at current burn rate without additional financing

Potential need for equity raise or debt financing if revenue growth disappoints - dilution risk to existing shareholders given $700M market cap

Negative ROA of -29% reflects asset-light model but also ongoing losses - path to positive ROE depends on sustained revenue growth

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - Prescription pharmaceutical demand for chronic cardiovascular disease treatment is largely non-discretionary and insulated from economic cycles. Patient population skews older (Medicare-eligible) with insurance coverage. However, commercial insurance mix and patient out-of-pocket costs can be affected by employment levels and benefit design changes during recessions.

Interest Rates

Rising rates create modest headwind through higher discount rates applied to future cash flows in DCF valuations, compressing biotech/pharma multiples. Company carries minimal debt ($20M convertible notes), so direct financing cost impact is negligible. However, as pre-profitable growth company, higher risk-free rates make equity financing more dilutive and reduce relative attractiveness versus established pharma with dividends.

Credit

Minimal direct credit exposure. Revenue is primarily from large pharmaceutical wholesalers (McKesson, AmerisourceBergen, Cardinal Health) with strong credit profiles. Patient access depends on insurance coverage, but cardiovascular medications receive priority formulary status. Royalty payments from Daiichi Sankyo (investment grade) carry low counterparty risk.

Live Conditions
S&P 500 FuturesRussell 2000 FuturesDow Jones Futures

Profile

growth - Company attracts biotech/specialty pharma growth investors focused on commercial execution and revenue inflection. Recent 186% revenue growth and 90% one-year return appeal to momentum investors. Negative FCF and lack of profitability exclude value and income investors. High volatility and binary outcomes (payer coverage decisions, competitive threats) suit risk-tolerant growth mandates. Institutional ownership likely concentrated in healthcare-focused funds.

high - Small-cap biotech with $700M market cap exhibits significant volatility driven by quarterly prescription data, payer coverage announcements, and competitive developments. Stock has demonstrated 74% six-month return, indicating momentum-driven trading. Limited analyst coverage and low float amplify price swings. Beta likely 1.5-2.0x relative to broader market.

Key Metrics to Watch
Weekly IQVIA prescription data (TRx and NBRx trends) - leading indicator of quarterly revenue
Gross-to-net percentage and payer mix (commercial vs Medicare Part D) - margin sustainability
Daiichi Sankyo ex-US royalty revenue growth - European uptake and Japanese launch progress
Operating cash flow and cash balance - liquidity runway and financing needs
Competitive prescription share in statin-intolerant segment versus PCSK9 inhibitors and Leqvio
Medicare Part D formulary positioning and prior authorization requirements - access barriers
Clinical trial progress for additional indications (homozygous familial hypercholesterolemia, pediatric) - pipeline value
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.